Company intelligence / Profile preview

Avexacare

Melbourne, Victoria, Australia

Ownership: Private
Development stage: Commercial

Overview

Avexa developed apricitabine (ATC), a nucleoside reverse transcriptase inhibitor for treatment-experienced HIV patients. The drug advanced through Phase IIb and into Phase III trials but was discontinued after failing to secure a licensing partner despite promising safety and efficacy data.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeNucleoside reverse transcriptase inhibitor
Industry: Biotech

Partnerships

Shire Pharmaceuticals (licensing agreement for apricitabine)

Beyond the preview

Go deeper on Avexacare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avexacare.

Explore the full profile